Multiplex genomic test of mutation and fusion genes in small biopsy specimen of lung cancer.

Q3 Pharmacology, Toxicology and Pharmaceutics Journal of Experimental Therapeutics and Oncology Pub Date : 2016-07-01
Fumihiro Oshita, Rika Kasajima, Yohei Miyagi
{"title":"Multiplex genomic test of mutation and fusion genes in small biopsy specimen of lung cancer.","authors":"Fumihiro Oshita,&nbsp;Rika Kasajima,&nbsp;Yohei Miyagi","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We evaluated multiple oncogenic mutations and fusion genes in small specimen obtained by bronchoscopy. Eight patients with lung cancer were recruited, 3 small cell lung cancer, 3 non-small cell lung cancer, 1 adenocarcinoma and 1 squamous cell carcinoma. A median value of extracted RNA and DNA amounts from specimen was 1573 ng (range 367.5 to 8900) and 6700 ng (range 550 to 68000 ng), respectively. We applied amplicon sequencing panels that cover exon regions of 41 genes related to lung tumorigenesis as well as total 61 major variants of ALK, ROS, RET or NTRK1 fusion transcripts. Nineteen of 41 gene mutations were detected in our isolated DNAs of 8 patients. We could detect four to eleven mutations in each specimen; however the mutation combination in each 8 patients were different. The most common genetic alterations were TP53, KMT2D, MET, NOTCH2 and SETD2, which were detected in 4 to 6 patients. We did not detect fusion transcripts of ALK, ROS, RET and NTRK1 in every specimen. In conclusion, multiplex genomic test was performed on small amounts specimen of bronchoscopy biopsy with a 100% success rate. Such testing is considered to be able to assist physicians in matching patients with approved or experimental targeted treatments.</p>","PeriodicalId":45335,"journal":{"name":"Journal of Experimental Therapeutics and Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Experimental Therapeutics and Oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

We evaluated multiple oncogenic mutations and fusion genes in small specimen obtained by bronchoscopy. Eight patients with lung cancer were recruited, 3 small cell lung cancer, 3 non-small cell lung cancer, 1 adenocarcinoma and 1 squamous cell carcinoma. A median value of extracted RNA and DNA amounts from specimen was 1573 ng (range 367.5 to 8900) and 6700 ng (range 550 to 68000 ng), respectively. We applied amplicon sequencing panels that cover exon regions of 41 genes related to lung tumorigenesis as well as total 61 major variants of ALK, ROS, RET or NTRK1 fusion transcripts. Nineteen of 41 gene mutations were detected in our isolated DNAs of 8 patients. We could detect four to eleven mutations in each specimen; however the mutation combination in each 8 patients were different. The most common genetic alterations were TP53, KMT2D, MET, NOTCH2 and SETD2, which were detected in 4 to 6 patients. We did not detect fusion transcripts of ALK, ROS, RET and NTRK1 in every specimen. In conclusion, multiplex genomic test was performed on small amounts specimen of bronchoscopy biopsy with a 100% success rate. Such testing is considered to be able to assist physicians in matching patients with approved or experimental targeted treatments.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肺癌小活检标本中突变和融合基因的多重基因组检测。
我们在支气管镜检查获得的小标本中评估了多种致癌突变和融合基因。8例肺癌患者,其中小细胞肺癌3例,非小细胞肺癌3例,腺癌1例,鳞状细胞癌1例。从标本中提取的RNA和DNA的中位数分别为1573 ng(范围为367.5至8900)和6700 ng(范围为550至68000 ng)。我们应用扩增子测序面板,覆盖了41个与肺肿瘤发生相关的基因的外显子区域,以及ALK、ROS、RET或NTRK1融合转录物的61个主要变体。在我们分离的8例患者的dna中检测到41个基因突变中的19个。我们可以在每个样本中检测到4到11个突变;但每8例患者的突变组合不同。最常见的基因改变是TP53、KMT2D、MET、NOTCH2和SETD2,在4 ~ 6例患者中检测到。我们没有在每个标本中检测到ALK、ROS、RET和NTRK1的融合转录本。综上所述,对少量支气管镜活检标本进行多重基因组检测,成功率为100%。这种测试被认为能够帮助医生将患者与已批准的或实验性的靶向治疗相匹配。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Giant Cervicodorsal Schwannoma. Clear cell variant of Oral Squamous cell carcinoma. Cervical carcinosarcoma presented in advanced stage after high grade cervical displasia. Glandular odontogenic cyst: a case report in an asymptomatic patient. Mebendazole in simultaneous combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR] generated utilizing a novel synthesis regimen: dual anti-neoplastic cytotoxicity against pulmonary adenocarcinoma (A549).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1